Resources for Researchers | Resources for Healthcare Professionals
With research comes progress.
With progress comes change.
PanCAN is leading large-scale, groundbreaking research initiatives that will be the catalyst for transforming the way pancreatic cancer is detected and treated. No single pancreatic cancer organization has taken on such a comprehensive approach. As an unbiased stakeholder, PanCAN is uniquely positioned to bring together the nation’s key thought leaders and experts in the pancreatic cancer research field to help patients thrive.
WHAT WE’VE ACCOMPLISHED TOGETHER
With approximately $126 million invested in research since 2003 and an additional $23 million investment this year
Research grants funded through a competitive, peer-review process
Patients’ tumors tested through our Know Your Tumor precision medicine service
Patients whose disease information has been collected in our Patient Registry
Precision Promise sites open to enroll eligible patients across the country
The Latest on Our Research Impact
See results from PanCAN’s Know Your Tumor® precision medicine service, showing that patients who are able to go on treatment that matches their tumor biology can live an average of one year longer than patients who aren’t.
Find out how PanCAN’s Patient Registry has provided important information about the prescription and use of pancreatic enzymes to alleviate debilitating pancreatic cancer symptoms.
Learn more about PanCAN’s Precision PromiseSM, our groundbreaking new approach to pancreatic cancer clinical trials, created to speed progress for patients by getting new and better treatments approved more quickly.
Want more research? See the top research stories from PanCAN’s research grants program, scientific and clinical initiatives and the field.
Support Our Mission
Since 2003, PanCAN has invested approximately $126 million in pancreatic cancer research – and we plan to invest another $23 million this year. This investment is only made possible by the support of our donors. We need your help now more than ever to continue to accelerate progress on this disease and help improve patient outcomes.